PPD Named Clinical Research Company of the Year for Second Consecutive Year
WILMINGTON, N.C. (Oct. 19, 2021) –
In addition to PPD winning the highest honor, individual PPD clinical researchers won gold and silver in both the Clinical Research Team and Start Up-Singles categories, as well as silver and bronze awards in the Aspiring Clinical Research Associate (CRA) category and bronze in the In-House CRA category.
“This is the second year in a row that PPD has won this award, and we are thrilled that our clinical researchers continue to be recognized by PharmaTimes for their talent, work ethic and commitment to this industry year after year,” said
The recognition demonstrates the high caliber of PPD’s clinical research professionals and the effectiveness of PPD’s award-winning training and development programs, such as the company’s Clinical Foundations Program and its
The Clinical Researcher of the Year Awards are the culmination of a rigorous series of assessments, including a three-stage competition concluding in presentations before a panel of experienced industry judges. The event was created to provide clinical research professionals an opportunity to benchmark their professional skills against their peers in a program of competency-based exercises developed through cross-industry collaboration.
PPD is a leading global contract research organization providing comprehensive, integrated drug development, laboratory and lifecycle management services. Our customers and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With more than 30,000 professionals worldwide, PPD has conducted clinical trials in more than 100 countries to help customers deliver life-changing therapies to improve health. We apply innovative technologies, therapeutic expertise and a firm commitment to quality to bend the cost and time curve of drug development and optimize value. For more information, visit www.ppd.com.
This news release contains forward-looking statements. These statements often include words such as “expect,” “believe,” “project,” “forecast,” “estimate,” “target” and other similar expressions. Although we believe these forward-looking statements are based on reasonable assumptions at the time they are made, you should be aware that many factors could affect our actual financial results, and therefore actual results might differ materially from those expressed in the forward-looking statements. Factors that might materially affect such forward-looking statements include, but are not limited to, the fragmented and highly competitive nature of the drug development services industry; changes in trends in the biopharmaceutical industry; our ability to keep pace with rapid technological changes that could make our services less competitive or obsolete; political, economic and/or regulatory influences and changes; the risks related to the proposed merger of PPD by Thermo Fisher Scientific Inc.; and other factors disclosed under the “Risk Factors” section in our periodic reports filed with the
+1 919 456 4425
+1 910 558 4186